Consideration of Ketogenic Metabolic Therapy as a Complementary or Alternative Approach for Managing Breast Cancer

Thomas N. Seyfried*, Purna Mukherjee1, Mehmet S. Iyikesici2, Abdul Slocum3, Miriam Kalamian4, Jean-Pierre Spinosa5 and Christos Chinopoulos6

1Biology Department, Boston College, Chestnut Hill, MA, United States, 2Medical Oncology, Kemerburgaz University Bahcelievler Medical Park Hospital, Istanbul, Turkey, 3Medical Oncology, Chemo Thermia Oncology Center, Istanbul, Turkey, 4Dietary Therapies LLC, Hamilton, MT, United States, 5Gynecologic and Breast Oncology, Clinique Cecil, Lausanne, Switzerland, 6Department of Medical Biochemistry, Semmelweis University, Budapest, Hungary

Breast cancer remains as a significant cause of morbidity and mortality in women. Ultrastructural and biochemical evidence from breast biopsy tissue and cancer cells shows mitochondrial abnormalities that are incompatible with energy production through oxidative phosphorylation (OxPhos). Consequently, breast cancer, like most cancers, will become more reliant on substrate level phosphorylation (fermentation) than on oxidative phosphorylation (OxPhos) for growth consistent with the mitochondrial metabolic theory of cancer. Glucose and glutamine are the prime fermentable fuels that underlie therapy resistance and drive breast cancer growth through substrate level phosphorylation (SLP) in both the cytoplasm (Warburg effect) and the mitochondria (Q-effect), respectively. Emerging evidence indicates that ketogenic metabolic therapy (KMT) can reduce glucose availability to tumor cells while simultaneously elevating ketone bodies, a non-fermentable metabolic fuel. It is suggested that KMT would be most effective when used together with glutamine targeting. Information is reviewed for suggesting how KMT could reduce systemic inflammation and target tumor cells without causing damage to normal cells. Implementation of KMT in the clinic could improve progression free and overall survival for patients with breast cancer.

Keywords: glycolysis, survival, glutaminolysis, non-toxic, fermentation, metastasis, inflammation

INTRODUCTION

Breast cancer persists as a significant cause of morbidity and mortality in woman. According to the American Cancer Society, the number of new cases and deaths from breast cancer in US woman is estimated to be 268,600 and 41,760, respectively, for 2019 (1). Indeed, breast cancer alone will account for 30% of all female cancers. Although the incidence of breast cancer is lower in black women than in white women, the death rate is 41% higher in blacks than in whites possibly due
in part to diet and lifestyle (2). The failure to effectively manage malignant breast cancer, and most malignant cancers for that matter, comes in large part from a misunderstanding on the origin of cancer. Although cancer has long been considered a genetic disease based on the somatic mutation theory (3–5), recent revelations have raised serious concerns that question the validity of this theory. Major concerns include:

1. The absence of gene and chromosomal mutations in some cancers (6–9). Indeed, Greenman et al. found no mutations following extensive sequencing in 73/210 cancers (3), while Parsons et al. found no mutations in the P53, the P13K, and the RB1 pathways in the Br20P tissue sample of a glioblastoma patient (10). Such samples should not exist according to the somatic mutation theory.

2. The presence and clonal expansion of numerous so-called driver gene mutations in a broad range of normal human tissues including breast tissue (11–15). It is not clear how the somatic mutation theory can account for malignant tumors that have no mutations or for normal cells and tissues that express driver mutations.

3. The absence of breast cancer and most other cancers in chimpanzees despite having about 98.5% gene and protein sequence identity with humans even at the BRCA1 locus (16–19). Indeed, breast cancer has never been documented in a female chimpanzee suggesting that diet and lifestyle issues, rather than genetic mutations, are largely responsible for the disease (18, 20).

4. The nuclear/cytoplasm transfer experiments showing that normal cells and tissues can be produced from tumorigenic nuclei as long as the tumorigenic nuclei are localized in cytoplasm containing normal mitochondria (21). Furthermore, recent studies show that normal mitochondria can down-regulate multiple oncogenic pathways and growth behavior in metastatic breast cancer cells (22, 23). These findings show that normal mitochondrial function can suppress tumorigenesis regardless of the gene or chromosomal abnormalities that might be present in the tumor nucleus. Viewed collectively, these findings suggest that the somatic mutations found in breast cancer and in most other cancers are not the primary cause of the disease. It is therefore unlikely that therapeutic strategies based on the somatic mutation theory will have major impact on the management of most cancers including breast cancer.

### THE MITOCHONDRIAL METABOLIC THEORY OF CANCER

Emerging evidence indicates that most if not all cancers display deranged energy metabolism (24–35). It is well-documented that the tumor cells found in most cancerous tissues including breast cancer tissue, have abnormalities in the number, structure, and function of their mitochondria (26, 27, 29, 33, 36–42). These abnormalities would compromise efficient energy production through oxidative phosphorylation (OxPhos). Figure 1 documents ultrastructural abnormalities in breast cancer mitochondria that are linked to abnormalities in proteins of the electron transport chain (43). In addition to abnormalities in mitochondrial membranes, breast cancer cells also express abnormalities in mitochondrial-associated membranes (MAM), that would further reduce energy production through OxPhos (44, 45). Consequently, increased fermentation metabolism would be necessary to compensate for OxPhos deficiency in order to maintain sufficient energy for breast cancer viability and growth.

### AEROBIC FERMENTATION OF GLUCOSE AND GLUTAMINE IN CANCER CELLS

Glucose and glutamine are the major fermentable fuels used by cancer cells with impaired OxPhos (39, 46). Glucose is fermented to lactic acid through glycolysis in the cell cytoplasm, while glutamine is fermented to succinic acid through glutaminolysis in the tricarboxylic acid (TCA) cycle. Notably, both fermentation processes can generate energy in the presence or absence of oxygen through substrate level phosphorylation (SLP) at the pyruvate kinase reaction in glycolysis and at the succinate ligase reaction in glutaminolysis, respectively (46). Warburg first described the aerobic fermentation of glucose as a major phenotype of most cancers (47–51). This metabolic phenotype has become known as the Warburg effect (52). In contrast to the Pasteur effect, where fermentation is suppressed in the presence of oxygen, the Warburg effect involves robust glucose-derived lactic acid fermentation even in the presence of 100% oxygen (aerobic fermentation).

### GLUTAMINOLYSIS

In addition to aerobic fermentation in the cytoplasm, glutaminolysis can also support high-energy phosphate synthesis in the mitochondria through the sequential conversion of glutamine-glutamate-alpha-ketoglutarate-succinyl CoA-succinate (Figure 2) (46). ATP synthesis through the succinate-CoA ligase reaction in the TCA cycle can compensate for reduced ATP synthesis through either glycolysis or OxPhos. We recently proposed that most of the ATP synthesized in tumor cells would come from mitochondrial substrate level phosphorylation (mSLP) at the succinate ligase reaction (46). Evidence showing that mSLP can compensate for OxPhos deficiency in cancer is emerging (57–60). mSLP could also compensate for minimal energy production through glycolysis due to the predominance of the glycolytic pyruvate kinase M2 (PKM2) isform, which produces less ATP than the PKM1 isform (61). The PKM2 isform is predominant in many cancers including breast cancer (62, 63). As Q is the single-letter designation of glutamine, the aerobic fermentation of glutamine through mSLP was recently defined as the Q effect; which has been recognized as the missing link in the mitochondrial metabolic theory of cancer (32, 46, 64, 65).
Unfortunately, the glutaminolysis pathway and the role of glutamine and mSLP was unknown to Warburg (46). We find it remarkable that nearly all of the major reviews or previous studies on cancer energy metabolism have not addressed or possibly even recognized the role of SUCL activity and mSLP, as a compensatory energy mechanism for deficient OxPhos. We consider mSLP as the key mechanism that underlies energy production in tumor cells with defective respiration (46).

Aerobic fermentation (Warburg effect) is a common metabolic phenotype in breast cancer regardless of histopathological type, grade, or gene expression profile (24, 66–74). In addition to glucose, glutamine is the other major fuel necessary for breast cancer cells (73, 75–78). The elevated utilization of glucose and glutamine becomes necessary to sustain the viability of OxPhos-impaired cancer cells through SLP in the cytoplasm and mitochondria, respectively. The Q-effect provides a rational explanation for the high glutamine use in cells with compromised OxPhos (46). The aerobic fermentation of glucose and glutamine in cancer cells would be the expected consequence of impaired OxPhos, as fermentation can compensate for insufficient respiration. Some have suggested that the function of the Warburg-effect is to provide a growth advantage for tumor cells. This is a teleological explanation, i.e., design with a purpose or intelligent design, which should not be part of modern biological thought (79–81). Cells do not make choices or have preferences, but simply respond to conditions in their internal and external environments according to evolutionarily designed metabolic programs. As proliferation, rather than quiescence, is the default state of metazoan cells (8, 82), unbridled proliferation becomes the consequence when fermentation gradually replaces respiration in cancer cells (21, 83, 84). Indeed, unbridled proliferation was the dominant growth phenotype of all organisms that existed on the planet before oxygen entered the atmosphere some 2.5 billion years ago (83). Hence, glucose and glutamine become the drivers of cancer cell fermentation and growth.

Impaired OxPhos together with compensatory fermentation leads to the accumulation of reactive oxygen species (ROS) (85–87). ROS are carcinogenic and mutagenic, and are largely responsible for the genomic instability and mutations seen in tumor cells (85, 87–93). In other words, the mutations seen in tumor cells arise as a consequence of impaired energy metabolism (32, 64). Oncogenes such as Hif-1alpha, Myc, Ras, BRAF, etc., facilitate the dependence of tumor cells on glucose and glutamine while defects in the tumor suppressor genes p53 and pRb will compromise OxPhos function thus causing further dependency on fermentation for growth (28, 46, 84, 94–99). These genes mutations are linked to breast cancer and other cancers through mitochondrial dysfunction. Compromised OxPhos would require compensatory glucose and glutamine fermentation to maintain membrane pump activity and tumor cell viability (64, 100). A mutation in the p53 gene was found to increase glucose consumption and the
Warburg effect, whereas the retinoblastoma Rb protein was found to increase glutamine metabolism through an effect on the E2F-3 transcription factor (101, 102). Mutations in these and in other oncogenes, and tumor suppressor genes, have been detected in breast cancer cells (103, 104). It is interesting that Her2 signaling in breast tumor promotes glycolysis and glucose utilization with lactate accumulation (105). Moreover, the ErbB2 targeting antibody, trastuzumab (Herceptin), inhibits glycolysis via downregulation of HSF1 and LDH-A in ErbB2-positive cancer cells. The results of Ding suggest that ErbB2 not only promotes glycolysis, but also inhibits mitochondrial oxidative phosphorylation by decreasing ETC activities (106). Mutations in the BRCA1 gene, which is known to play an important role in maintaining metabolic homeostasis, have also been linked to elevated glycolysis and other metabolic disturbances (107, 108). As no known inherited breast cancer gene is 100% penetrant, germline mutations are considered secondary risk factors and cannot therefore be considered primary causes of cancer. A penetrance of 100% is necessary for any tumor gene to be considered a primary cause of cancer. OxPhos impairment with compensatory glucose and glutamine fermentation is the common underlying phenotype of most if not all cancers.

### ORIGIN OF METASTASIS

Metastasis involves the dissemination of cancer cells from the primary tumor to surrounding tissues and to distant organs and is the primary cause of cancer morbidity and mortality (109). Most tumors that fail to show local invasion or metastasis are considered benign and do not pose serious risk despite expressing a majority of the so called “Hallmarks of Cancer” (110). Tumor cell metastasis involves a stereotypic cascade of biological phenomenon including local invasion, intravasation into the blood, survival in the circulation, immune suppression, extravasation from the blood, and growth in a distant organ or tissue (111). Identification of the unique features of the metastatic cell can expand understanding of metastasis and facilitate rational therapeutic strategies based on knowledge of cell biology and biochemistry.

Two major theories have been advanced to explain metastasis that include the epithelial-mesenchymal transition (EMT), and the macrophage fusion hybrid hypothesis. The EMT is the dominant explanation and is based on the somatic mutation theory of cancer. The EMT proposes that an initial series of random mutations disturb cell-cell interaction causing a normal epithelial cell to transform into an invasive mesenchymal cell. Further additional random mutations cause the mesenchymal cell to intravasate, and subsequently extravasate into the parenchyma at some distant organ site (4, 112). Once established at the distant site, the metastatic tumor cells transform back to an epithelial phenotype via the so called mesenchymal epithelial transition (MET) (4, 112). No explanation has been presented, however, as to how the multiple random gene mutations responsible for the initial events of the metastatic cascade could be reversed or suppressed during the MET (4). Despite its linkage to phenomenology, the EMT is considered the dominant explanation for breast cancer metastasis (113).

In contrast to the EMT, the macrophage fusion hybrid hypothesis posits that metastasis arises from macrophages either directly or indirectly from the fusion of macrophages with neoplastic cells (109, 114–117). The metastatic breast cancer cell, like many metastatic cancer cells, expresses characteristics of myeloid cells and macrophages (109, 114, 118–125). These characteristics include phagocytosis, fusogenicity, and expression of multiple myeloid/macrophage biomarkers. Fusion hybridization could also better account for the large degree of cellular and genetic heterogeneity seen in metastatic breast cancer than can the EMT (126, 127). A macrophage origin of metastasis is also more consistent with Paget’s “seed soil” hypothesis than is an origin based on EMT (109, 128, 129). Macrophages (seeds) are known to infiltrate organs (soil) non-randomly (109). As glutamine is a major fuel for macrophages (130, 131), targeting the availability of glutamine together with glucose becomes a rational, yet largely overlooked, therapeutic strategy for managing metastatic cancer (60).

### CURRENT STANDARD OF CARE (SOC) FOR BREAST CANCER

Current standard management of breast cancer requires histological diagnosis obtained by core needle biopsy prior to surgical procedure (132). Therapies for breast cancer depend largely on the stage, grade, and the biology of the disease. Surgery and radiotherapy (breast and axilla) are used for local disease control, staging, and tumor extirpation. It is important to mention, however, that the extent of surgery and radiotherapy are not linked to a survival advantage (133). Chemotherapy, hormone therapy (tamoxifen, aromatase inhibitor, or one followed by the other), targeted therapies, trastuzumab (Herceptin) and pertuzumab (Perjeta), or combinations of these are designed to destroy local residual cancer cells and latent metastasis, while also reducing the risk of recurrence. Mechanical interventions (core needle biopsies and surgery) can cause wound-induced inflammatory oncotaxis, which influences the natural history of breast cancer (129). Data from several studies show that biopsies and surgery can cause inflammatory oncotaxis thus increasing tissue angiogenesis and spread of tumor cells (134–140). Invasive and metastatic behavior would be expected for breast cancer cells with myeloid properties (123). Some have hypothesized that growth factor stimulation in response to intraoperative tissue damage, can increase HER2 receptor activation in incompletely resected pre-invasive breast cancer thus increasing risk for tumor cell proliferation and spread (141). Procedures that might elevate blood glucose or insulin levels should be avoided, as glucose is known to accelerate breast cancer development (142–147). Products used in anesthesia might also increase blood glucose and insulin levels (148). The type of anesthesia and analgesia used during and after surgery should be carefully monitored for possible influence on glucose and insulin metabolism (149). Glucocorticoids, which are given to some breast cancer
patients, can also elevate blood glucose levels thus supporting glucose-dependent aerobic fermentation. In addition to elevating blood glucose, glucocorticoids can also block estrogen-induced apoptosis to further stimulate breast cancer growth (150). Hence, risk for tumor spread can be associated with accepted procedures used in breast cancer management.

**KETOCNIC METABOLIC THERAPY**

Ketogenic metabolic therapy (KMT) is emerging as an effective complementary or alternative therapeutic strategy for managing a broad range of malignant cancers including breast cancer (151–160). Calorie restriction and low-carbohydrate high-fat ketogenic diets (KD) reduce the glucose needed to propel the Warburg effect while also elevating ketone bodies (34). Cancer cells cannot effectively use ketone bodies or fatty acids for ATP synthesis through OxPhos due to defects in the number, structure, and function of their mitochondria (34, 46). Moreover, ketone bodies and fatty acids cannot be fermented, and thus cannot effectively replace glucose and glutamine as an alternative energy source for cancer (46). Bartmann et al. showed that the major ketone body, beta-hydroxybutyrate, could not stimulate breast tumor growth in vitro (161). Hence, KMT becomes a putative therapeutic strategy for managing most cancers including breast cancer (34).

There have been reports, however, suggesting that some cancers, including breast cancer, can oxidize ketone bodies and fatty acids for growth (162–165). The uptake of ketone bodies or fatty acids together with oxygen consumption in tumor cells is not proof that the ketone bodies or fatty acids can be used to generate energy through OxPhos (34, 46, 166). Indeed, Kuok et al. recently showed that palmitate could increase oxygen consumption rate (OCR) by stimulating ATP usage and insulin secretion rather than by increasing beta-oxidation (167). Fatty acids are potent swelling and uncoupling agents that can stimulate insulin secretion and glucose/glutamine consumption thus making it appear as if tumor cells can metabolize fatty acids for energy (166, 168–170). In other words, fatty acids can stimulate utilization of glucose and glutamine. Many tumor cells including breast cancer cells will store fatty acids as lipid droplets (166, 171, 172). Lipid droplet storage is considered a protection mechanism from the lethal effects of saturated fatty acids in cells that cannot metabolize fats for energy (171–174). If tumor cells could use fatty acids for growth, then water-only fasting and calorie restricted ketogenic diets should accelerate tumor growth, as these dietary changes elevate free fatty acids in the blood (175, 176). This is clearly not the case. Also, palmitic acid cannot support in vitro tumor cell growth in the absence of glucose and glutamine. Any disruption of the mitochondrial proton motive gradient will provide ATP for the F1-F0 ATP synthase thus hydrolyzing ATP rather than synthesizing ATP (46). mSLP will provide ATP for F1-F0-ATP synthase in an effort to maintain a moderate mitochondrial membrane potential and prevent reversal. Based on the foundational biological principle that structure determines function (43, 168, 177, 178), ketone bodies and fatty acids cannot serve as major respiratory fuels for tumor cells containing defects in mitochondrial structure and function (46, 84). Hence, it would be helpful to include evidence of normal mitochondria ultrastructure and electron transport chain activities in reports indicating that ketone bodies and fatty acids are fuels for OxPhos-generated ATP synthesis in cancer cells.

Depletion of fermentable fuels from KMT will facilitate catastrophic tumor cell death. Ketogenic diet appears to work better when used with glutamine targeting and is consumed in restricted amounts (60). The simultaneous targeting of glycolysis and glutaminolysis is now emerging as a potential therapeutic strategy for managing a broad range of cancers including breast cancer (60, 179, 180). KMT reduces circulating levels of glucose and insulin that are needed for rapid tumor growth (176). Excessive consumption of ketogenic diets, however, can provoke tumor growth by causing insulin insensitivity and glucose elevation (176, 181). Hence, KMT becomes a logical therapeutic strategy for managing breast cancer when used correctly.

The microenvironment of many tumors is hypoxic, acidic, and enriched with glucose and glutamine. Under KMT, this pro-tumorigenic microenvironment becomes less inflamed (84, 182, 183). Restricted KDs and calorie restriction are antiinvasive, antiangiogenic, anti-inflammatory, and capable of killing tumor cells through a pro-apoptotic mechanism (181–188). Metabolism of the major circulating ketone body, D-beta-hydroxybutyrate, reduces reactive oxygen species production through the mitochondrial Co-enzyme Q couple in normal cells, while simultaneously elevating oxidative stress in tumor cells (34, 189–191). Implementation of KMT prior to any surgical procedure could also benefit patients (152). KMT should decrease the need for dexamethasone pretreatment, a problematic therapy that can inadvertently increase availability of glucose to the tumor cells while also inhibiting chemotherapy-induced apoptosis (192–194). It is well-known that glucose and hyperglycemia contribute to rapid breast cancer growth (146, 195, 196). Consequently, KMT could reduce inflammation and glucose systemically, thus enhancing the anti-tumorigenic properties of the microenvironment.

Therapeutic ketosis is linked to reduced blood glucose levels and to elevated ketone body levels within normal physiological ranges (Figure 3). Reduction of carbohydrate intake after breast cancer diagnosis in women reduces risk of recurrence (198). Evidence shows that therapeutic ketosis can act synergistically with several drugs and procedures to enhance cancer management while improving both progression-free and overall survival (34, 154, 199, 200). For example, hyperbaric oxygen therapy (HBOT) increases oxidative stress on tumor cells especially when used alongside therapies that reduce blood glucose and elevate blood ketones (201). By reducing blood glucose, KMT would also reduce the immunosuppressive effects of lactic acid in the tumor microenvironment (202). Recent studies show that therapeutic ketosis can facilitate drug delivery through the blood-brain barrier (60, 203). This would be important in helping to target breast cancer cells that metastasize to the brain. Also, it has been reported that caloric restriction reduces leaky tumor blood vessels by increasing neovascular smooth muscle (183). This could account, in part,
for a better drug delivery to solid tumors under KMT. The antimalarial drug, chloroquine, neutralizes lysosomal pH reducing for a better drug delivery to solid tumors under KMT. The anti-malarial drug, chloroquine neutralizes lysosomal pH reducing phagocytosis and autophagy, and thus depriving invasive and metastatic tumor cells from obtaining glucose and glutamine (34, 204, 205). Chloroquine can also inhibit mitochondrial diaphorases that oxidize NADPH to NAD+, which in turn would reduce mSLP (34, 207). The glutaminase inhibitor, 6-diazo-5-oxo-L-norleucine (DON), is a powerful glutamine-targeting drug that can work synergistically with a restricted KD for managing brain cancer and metastasis (60, 208, 209). Hence, KMT can, (a), target the multiple drivers of rapid tumor growth, (b), facilitate drug delivery to the tumor tissue, (c), work synergistically with glutamine-targeting drugs, and, (d), enhance the metabolic efficiency in normal healthy cells. To our knowledge, there are currently no cancer therapies that can target these multiple drivers of tumor growth while simultaneously protecting normal cells.

THE GLUCOSE KETONE INDEX

The Glucose Ketone Index (GKI) is a single number representing the glucose-to-ketone ratio (expressed in mmol/L), and was developed as a guide for evaluating therapeutic efficacy of KMT. The GKI serves as a proxy for the degree of metabolic stress placed on tumor cells through the reduction of circulating glucose and elevation of ketone bodies (beta-hydroxybutyrate, acetoacetate) (34, 197). A GKI value of 1.0 or below has been suggested as the therapeutic goal for cancer management (Figure 4). However, therapeutic GKI values can be difficult to achieve for many cancer patients. For example, tumor burden, toxic treatment protocols, and emotional and physical stress can combine to elevate blood glucose and insulin levels thus preventing the patient from achieving therapeutic GKI values (34, 84, 210). Further refinement of existing KMT therapies along with introduction of new therapies may serve to mitigate this obstacle.

KMT AS A COMPLEMENTARY OR ALTERNATIVE TO SOC

KMT has been used together with low dose chemotherapy and other treatments to manage tumor progression in a woman with stage IV triple negative breast cancer (154). The woman responded well to the combined treatment, and initially reported as a complete therapeutic response. Although overall survival exceeded the median expected for her stage and grade, she eventually succumbed to her cancer. A failure to continue with the KMT protocol was considered responsible in part for her tumor recurrence (154). Nevertheless, a subsequent clinical study showed that a ketogenic diet combined with carboplatin/paclitaxel, hyperthermia, and hyperbaric oxygen therapy significantly improved progression-free and overall survival in patients with advanced non-small cell lung cancer (211). Currently, neoadjuvant therapies are commonly prescribed for a subset of invasive or late-stage cancers, including breast cancers. KMT initiated soon after diagnosis and prior to surgery may prove to be a non-toxic adjunct treatment capable of downgrading the aggressive and invasive nature of the cancer, thereby increasing the efficacy of subsequent treatments (212). It is our view that improvements in selection, dosage, timing, and scheduling of drugs, diet,
and procedures will offer benefits in survival and quality of life to patients with advanced metastatic breast cancer when used as a complementary or alternative therapeutic strategy alongside the SOC (Figure 5). The Press-Pulse therapeutic strategy for cancer management was based on the concept of Arens and West, who described how the simultaneous occurrence of “press-pulse” disturbances was responsible for the extinction of organic populations during prior evolutionary epochs (213). A similar concept can be used to show how tumors can be slowly degraded. Optimization of dosing, timing, and scheduling of KMT used together with synergistic drugs and procedures will facilitate the eradication of breast tumor cells with minimal patient toxicity. This therapeutic strategy can serve as a framework for the design of clinical trials for the non-toxic management of most cancers (34). Further details are described in Figure 5.

**CONCLUSIONS**

Breast cancer, like many cancers, are dependent on fermentation metabolism for growth. Substrate level phosphorylation drives the fermentation metabolism of tumor cells using glucose and glutamine as major fuels in the cytoplasm and...
mitochondria, respectively. The protracted replacement of respiration with fermentation in cancer cells leads to unbridled cell proliferation. Fusion hybridization of epithelial-derived cancer stem cells with glutamine-dependent tissue macrophages is an alternative explanation to the epithelial-mesenchymal-transition for the origin of metastatic breast cancer cells. The aim of our review is to illustrate that the restriction of glucose and glutamine together with elevation of non-fermentable ketone bodies offers a complementary or alternative therapeutic strategy to the SOC for the non-toxic management of breast cancer. It is our view that KMT could improve progression-free and overall survival for most breast cancer patients.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. (2019) 69:7–34. doi: 10.3322/caac.21551
2. Desantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin. (2019) 69:211–33. doi: 10.3322/caac.21555
3. Greenman C, Stephens P, Smith R, Dalglish GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature. (2007) 446:153–8. doi: 10.1038/nature05610
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013
5. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. (2013) 339:1546–58. doi: 10.1126/science.1235122
6. Bayreuther K. Chromosomes in primary neoplastic growth. Nature. (1960) 186:6–9. doi: 10.1038/186006a0
7. Pitot HC. Some biochemical aspects of malignancy. Ann Review Biochem. (1966) 35:335–68. doi: 10.1146/annurev.bi.35.070166.002003
8. Soto AM, Sonnenschein C. The somatic mutation theory of cancer: growing problems with the paradigm? Bioessays. (2004) 26:1097–107. doi: 10.1002/bies.200807
9. Baker SG. A cancer theory keruffle can lead to new lines of research. J Natl Cancer Inst. (2015) 107:du405. doi: 10.1093/jnci/dju055
10. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. (2008) 321:1807–12. doi: 10.1126/science.1163482
11. Martincorena I, Campbell PL. Somatic mutation in cancer and normal cells. Science. (2015) 349:1483–9. doi: 10.1126/science.aab4082
12. Chanock SJ. The paradox of mutations and cancer. Science. (2018) 362:893–4. doi: 10.1126/science.aav5697
13. Martincorena I, Fowler JC, Wabik A, Lawson ARJ, Abascal F, Hall MJW, et al. Somatic mutant clones colonize the human exophagus with age. Science. (2018) 362:911–7. doi: 10.1126/science.aau3879
14. Yizhak K, Aguett E, Kim J, Hess JM, Kubler K, Grimsby J, et al. RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. Science. (2019) 364:aea0726. doi: 10.1126/science.aaw726
15. Yokoyama A, Kakiku N, Yoshizato T, Nannya Y, Suzuki H, Takeuchi Y, et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature. (2019) 565:312–7. doi: 10.1038/s41586-018-0811-x
16. Huttley GA, Eastell S, Southey MC, Tesoriero A, Giles GG, Mccredie MR, et al. Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees. Aust Breast Cancer Family Study Nat Genet. (2000) 25:410–3. doi: 10.1093/carcin/22.3.253
17. Puente XS, Velasco G, Gutierrez-Fernandez A, Bertranpetit J, King MC, Lopez-Otin C. Comparative analysis of cancer genes in the human and chimpanzee genomes. BMC Genomics. (2006) 7:15. doi: 10.1186/1471-2164-7-15

AUTHOR CONTRIBUTIONS

TS conceived and wrote the review. MI, AS, MK, and J-PS contributed clinical information and edited the review. PM and CC contributed scientific information to the review.

ACKNOWLEDGMENTS

We thank the Foundation for Metabolic Cancer Therapies, CrossFit Inc., the Nelson and Claudia Peltz Foundation, Joseph C. Maroon, the George Yu Foundation, Kenneth Rainin Foundation, and the Boston College Research Expense Fund for their support.
33. Srinivasan S, Guha M, Dong DW, Whelan KA, Ruthel G, Uchikado Y, et al. Disruption of cytochrome c oxidase function induces the warburg effect and metabolic reprogramming. Oncogene. (2016) 35:1585–95. doi: 10.1038/onc.2015.227

34. Seyfried TN, Yu G, Maroon JC, D’Agostino DP. Press-pulse: a novel therapeutic strategy for the metabolic management of cancer. Nutr Metab. (2017) 14:19. doi: 10.1186/s12986-017-0178-2

35. Da Silva I, Da Costa Vieira R, Stella C, Loturco E, Carvalho AL, Vea C, et al. Inborn-like errors of metabolism are determinants of breast cancer risk, clinical response and survival: a study of human biochemical individuality. Oncotarget. (2018) 9:31664–81. doi: 10.18632/oncotarget.25839

36. Rouiller C. Physiological and pathological changes in mitochondrial morphology. Int Rev Cytol. (1960) 9:227–92. doi: 10.1016/S0074-7696(08)62748-5

37. Roddy HJ, Silverberg SG. Ultrastructural analysis of apocrine carcinoma of the human breast. Ultrastruct Pathol. (1980) 1:385–93. doi: 10.3109/01913128009141441

38. Gadaleanu V, Craciun C. Malignant oncocytoma of the breast. Zentralbl Allg Pathol. (1987) 133:279–83.

39. Pelicano H, Xu RH, Du M, Feng L, Carew JS, et al. Mitochondrial alteration of expression levels of the oxidative phosphorylation system. Breast Cancer Res Treat. (2012) 136:347–54. doi: 10.1007/s10549-012-2283-2

40. Arismendi-Morillo G, Castellano-Ramirez A, Seyfried TN. Ultrastructural characterization of the Mitochondria-associated membranes abnormalities in human astrocytomas: functional and therapeutic implications. Ultrastruct Pathol. (2017) 41:234–44. doi: 10.1080/019131217.2017.1300618

41. Zeczycki TN, Whelan J, Hayden WT, Brown DA, Shaikh SR. Increasing levels of cardiolipin differentially influence packing of phospholipids found in the mitochondrial inner membrane. Biochem Biophys Res Commun. (2014) 450:366–71. doi: 10.1016/j.bbrc.2014.05.133

42. Jogalekar MP, Serrano EE. Morphometric analysis of a triple negative breast cancer cell line in hydrogel and monolayer culture environments. Breast Cancer Res Treat. (2018) 6:e4340. doi: 10.7717/peerj.4340

43. Putignani L, Raffa S, Pescosolido R, Aimati L, Signore F, Torrisi MR, et al. Alteration of expression levels of the oxidative phosphorylation (OXPHOS) in breast cancer cell mitochondria. Breast Cancer Res Treat. (2019) 2:200. doi: 10.1038/s42003-019-0455-x

44. Arisendi-Morillo G, Castellano-Ramirez A, Seyfried TN. Ultrastructural characterization of the Mitochondria-associated membranes abnormalities in human astrocytomas: functional and therapeutic implications. Ultrastruct Pathol. (2017) 41:234–44. doi: 10.1080/019131217.2017.1300618

45. Morciano G, Marchi S, Morganti C, Sbano L, Bittremieux M, Lindau: K. Triltsch (1969). p. 1–9.

46. Warburg O. On the origin of cancer cells. Int Rev Cytol. (1960) 9:227–92. doi: 10.1016/S0074-7696(08)62748-5

47. Warburg O. On the origin of cancer cells. Nature. (2016) 496:238–42. doi: 10.1038/nature12986

48. Choucroun ET, Pell VR, Gaude E, Akentievic D, Sundlier SY, Robb EL, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. (2014) 515:431–5. doi: 10.1038/nature13909

49. Warburg O. Mitochondria: organelle transplant ation: a review of the origin of cancer cells. Int Rev Cytol. (2011) 224:1–30. doi: 10.1016/B978-0-12-375982-9.00005-9

50. Putignani L, Raffa S, Pescosolido R, Aimati L, Signore F, Torrisi MR, et al. Alteration of expression levels of the oxidative phosphorylation system. Breast Cancer Res Treat. (2012) 136:347–54. doi: 10.1007/s10549-012-2283-2

51. Zeczycki TN, Whelan J, Hayden WT, Brown DA, Shaikh SR. Increasing levels of cardiolipin differentially influence packing of phospholipids found in the mitochondrial inner membrane. Biochem Biophys Res Commun. (2014) 450:366–71. doi: 10.1016/j.bbrc.2014.05.133

52. Rogalekar MP, Serrano EE. Morphometric analysis of a triple negative breast cancer cell line in hydrogel and monolayer culture environments. PeerJ. (2014) 20:510–23. doi: 10.7717/peerj.4340

53. Morciano G, Marchi S, Morganti C, Sbano L, Bittremieux M, Lindau: K. Triltsch (1969). p. 1–9.

54. Morciano G, Marchi S, Morganti C, Sbano L, Bittremieux M, Lindau: K. Triltsch (1969). p. 1–9.
73. Reis LMD, Adamoski D, Ormitz Oliveira Souza R, Rodrigues Ascencio CF, Sousa De Oliveira KR, Correa-Da-Silva F, et al. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase-inhibition-resistant triple-negative breast cancer cells. J Biol Chem. (2019) 294:9342–57. doi: 10.1074/jbc.RA119.008180

74. Rosso M, Lapyskiy V, Besso M, Monge M, Reventos J, Canals F, et al. Characterization of the molecular changes associated with the overexpression of a novel epithelial cadherin splice variant mRNA in a breast cancer model using proteomics and bioinformatics approaches: identification of changes in cell metabolism and an increased expression of lactate dehydrogenase B. Cancer Metab. (2019) 7:5. doi: 10.1186/s40170-019-0196-9

75. Katt WP, Ramachandran S, Erickson JW, Cerione RA. The causes of cancer revisited: mitochondrial malignancy and ROS-induced oxidative damage in carcinogenesis. Toxicol Pathol. (2019) 47:2392–404. doi: 10.1080/01926239.2019.1664893

76. Van Geldermalsen M, Wang Q, Nagarajah R, Marshall AD, Thoeng A, et al. Reactive oxygen species and cancer paradox: to promote or to suppress? Crit Rev Oncog. (2010) 18:43–73. doi: 10.1615/CritRevOncog.v18.i1-2.40

77. Szent-Györgyi A. The living state and cancer. Proc Natl Acad Sci USA. (1977) 74:2844–7. doi: 10.1073/pnas.74.7.2844

78. Seyfried TN. Nothing in cancer biology makes sense except in the light of evolution In: Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer. Hoboken, NJ: John Wiley & Sons (2012). p. 112:1–12. doi: 10.1002/9781118138311.ch15

79. Mayr E. The Growth of Biological Thought: Diversity, Evolution, and Inheritance. Cambridge: Belknap Harvard (1982).

80. Schlesinger AB. Explaining Life. New York, NY: McGraw-Hill, Inc (1994).

81. Seyfried TN. Nothing in cancer biology makes sense except in the light of evolution In: Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer. Hoboken, NJ: John Wiley & Sons (2012). p. 9:686. doi: 10.1038/srep00866

82. Demas DM, Demo S, Fallah Y, Clarke R, Nephew KP, Althouse et al. Inhibition of oxidative metabolism leads to p53 genetic inactivation and transformation in neural stem cells. Cancer Cell. (2016) 35:3201–8. doi: 10.1016/j.cce.2015.03.81

83. Szent-Györgyi A. The living state and cancer. Proc Natl Acad Sci USA. (1977) 74:2844–7. doi: 10.1073/pnas.74.7.2844
114. Pawelek JM. Cancer-cell fusion with migratory bone-marrow-derived cells as an explanation for metastasis: new therapeutic paradigms. *Fat Oncol.* (2008) 4:449–52. doi: 10.21277/1796694.4.449

115. Pawelek JM, Chakraborty AK. The cancer cell-leukocyte fusion theory of metastasis. *Adv Cancer Res.* (2008) 101:397–444. doi: 10.1016/S0065-230X(08)30009-7

116. Powell AE, Anderson EC, Davies PS, Silk AD, Pelz C, Impey S, et al. Fusion between intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming. *Cancer Res.* (2011) 71:1497–505. doi: 110.1158/0008-5472.CAN-10-3323

117. Gast CE, Silk AD, Zourou I, Riegler L, Burkhart JG, Gustafson KT, et al. Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with rate and survival. *Sci Adv.* (2018) 4:eaa77828. doi: 10.1126/sciadv.aat7828

118. Marin-Padilla M. Erythropagocytosis by epithelial cells of a breast carcinoma. *Cancer.* (1977) 39:1085–1089. doi: 10.1002/1097-0142(197703)39:3<1085::AID-CNCRN282093012-3>CO;2-U

119. Ruff MR, Pert CB. Origin of human small cell lung cancer. *Science* 229:680. doi: 10.1126/science.229.4714.680

120. Ruff MR, Pert CB. Small cell carcinoma of the lung: macrophage-specific antigens suggest hemopoietic stem cell origin. *J Nutr* 135:102551. (2016) 15:164–86. doi: 10.2174/1871529X15666151102

121. Calvo F, Martin PM, Jabrane N, De Cremoux P, Magdelenat H. Human breast cancer cells share antigens with the myeloid monocyte lineage. *Br J Cancer.* (1986) 59:15–9. doi: 10.1038/bjc.1987.145

122. Kobayashi M, Sugimoto T, Okabayashi T, Okamoto K, Namikawa T, Tochika et al. Localization of thymidine phosphorylase in breast cancer tissue. *Mol Mol Morphol.* (2005) 38:112–7. doi: 10.1016/s0026-8838(05)00089-1

123. Ruff MR, Pert CB. Origin of human small cell lung cancer. *Science* 229:680. doi: 10.1126/science.229.4714.680

124. Calvo F, Martin PM, Jabrane N, De Cremoux P, Magdelenat H. Human breast cancer cells share antigens with the myeloid monocyte lineage. *Br J Cancer.* (1986) 59:15–9. doi: 10.1038/bjc.1987.145

125. Kobayashi M, Sugimoto T, Okabayashi T, Okamoto K, Namikawa T, Tochika N, et al. Localization of thymidine phosphorylase in breast cancer tissue. *Mol Mol Morphol.* (2005) 38:112–7. doi: 10.1016/s0026-8838(05)00089-1

126. Huysentruyt LC, Seyfried TN. Perspectives on the mesenchymal origin of metastatic cancer. *Cancer Metastasis Rev.* (2010) 29:695–707. doi: 10.1007/s10591-010-9254-z

127. Schramm HM. Should EMT of cancer cells be understood as epithelial-myoeloid transition? *J Cancer.* (2014) 5:125–32. doi: 10.7150/jca.82422

128. Rowan DJ, Logunova V, Van Tuinen P, Olleau H, Peterson JF. Circulating breast carcinoma cells mimicking therapy-related acute myeloid leukemia. *Int J Surg Pathol.* (2017) 25:87–93. doi: 10.1016/j.ijsp.2016.06.022

129. Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. *Clin Cancer Res.* (2008) 14:1938–46. doi: 10.1158/1078-0432.CCR-07-0482

130. Weigett B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? *Nat Rev Clin Oncol.* (2009) 6:718–9. doi: 10.1038/nrclinonc.2009.166

131. Paget S. The distribution of secondary growths in cancer of the breast. *The Lancet.* (1889) 1:571–3. doi: 10.1016/S0140-6736(00)49915-0

132. Kawaguchi T. Organ preference of cancer metastasis and metastasis-related cell adhesion molecules including carbohydrates. *Cardiovasc Hematol Disord Drug Targets.* (2016) 15:164–86. doi: 10.2174/1871529X1566615102

133. Newsom-Petri P. Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection? *J Nutr.* (2001) 131:2515S–225. doi: 10.1093/jn/131.9.2515S

134. Ren W, Xia Y, Chen S, Wu G, Bazer FW, Zhou B, et al. Glutamine metabolism in macrophages: a novel target for obesity/type 2 diabetes. *Adv Nutr.* (2019) 10:321–30. doi: 10.1093/advances/nmy084

135. Wallis M, Tardivon A, Helbich T, Schreier I, European Society of Breast I. Guidelines from the European society of breast imaging for diagnostic interventional breast procedures. *Eur Radiol.* (2007) 17:581–8. doi: 10.1007/s00330-006-0408-x

136. Kurihara S, Lichtenztein DY, Keegan TH, Nelson DO, Clarke CA, Gomez SL. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. *JAMA.* (2014) 312:902–14. doi: 10.1001/jamaintern Med.2014.10707

137. Hofer SO, Molea G, Hermes RA, Wanebo HJ, Reichner JS, Hoekstra HJ. The effect of surgical wound on tumour development. *Eur J Surg Oncol.* (1999) 25:231–43. doi: 10.1053/ejso.1998.0634
diet, hyperthermia, and hyperbaric oxygen therapy for stage IV triple-negative breast cancer. *Cereus.* (2017) 9:e1445. doi: 10.7759/cereus.e1445

155. Klement RJ, Bandyopadhyay PS, Champ CE, Walach H. Application of Bayesian evidence synthesis to modelling the effect of ketogenic therapy on survival of high grade glioma patients. *Theor Biol Med Model.* (2018) 15:12. doi: 10.1186/s12976-018-0208-x

156. Cohen CW, Fontaine KR, Arend RC, Gower RA. A ketogenic diet is acceptable in women with ovarian and endometrial cancer and has no adverse effects on blood lipids: a randomized, controlled trial. *Nutr Cancer.* (2019) 71:1–11. doi: 10.1080/01635581.2019.1645864

157. Khodabakhshi A, Akbari ME, Mirzaei HR, Mehrad-Majd H, Kalaman M, Davoodi SH. Feasibility, safety, and beneficial effects of MCT-based ketogenic diet for breast cancer treatment: a randomized controlled trial study. *Nutr Cancer.* (2019) 9:1–8. doi: 10.1080/01635581.2019.150942

158. Licha D, Vidali S, Aminzadeh-Gohari S, Alka O, Breitkreuz L, Kohlbacher O, et al. Untargeted metabolomics reveals molecular effects of ketogenic diet on healthy and tumor xenograft mouse models. *Int J Mol Sci.* (2019) 20:3873. doi: 10.3390/ijms20163873

159. Mitchell T, Clarke L, Goldberg A, Bishop KS. Pancreatic cancer cachexia: the role of nutritional interventions. *Healthcare.* (2019) 7:89. doi: 10.3390/healthcare7030089

160. Weber DD, Aminzadeh-Gohari S, Tulipan J, Catalano L, Feichtinger RG, Koffer F. Ketogenic diet in the treatment of cancer - Where do we stand? *Mol Metab.* (2019) 11:668–68. doi: 10.1016/j.molmet.2019.06.026

161. Bartmann C, Janaki Raman SR, Floter J, Schulze A, Bahlke K, Willingstorfer J, et al. Beta-hydroxybutyrate. (3-OHB) can influence the energetic status of calcium release from endoplasmic reticulum. *Islets* (2019) 1864:344–57. doi: 10.1016/j.bbalip.2018.12.011

162. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiu HP, et al. UCP2 transports C4 metabolites out of mitochondria, regulating glucose and glutamine oxidation. *Cancer Res* (2014) 74:4261–70. doi: 10.1158/0008-5472.CAN-13-3722

163. Cheng H, Feng Z, Liu J, Zhao W, Liu J, Cao F. Inhibition of AMPK phosphorylation and apoptosis evading. *Oncol Lett* (2018) 15:2331–36. doi: 10.3892/ol.2018.9022

164. Giudetti AM, De Domenico S, Ragusa A, Lunetti P, Gaballo A, Franck J, et al. Specific lipid metabolic profile is associated with the epithelial mesenchymal transition program. *Biochim Biophys Acta Mol Cell Biol Lipids.* (2019) 1864:344–57. doi: 10.1016/j.bbalip.2018.12.011

165. Rodrigues LM, Uribe-Lewis S, Madhu B, Honess DJ, Stubbles M, Griffiths JR. The action of beta-hydroxybutyrate on the growth, metabolism and global histone H3 acetylation of spontaneous mouse mammary tumours: evidence of a beta-hydroxybutyrate paradox. *Cancer Metab.* (2017) 5:4. doi: 10.1186/s40170-017-0146-v

166. Simard A, Leblanc A, D’Amours D, Bouchard-Ayme A, Parent RA, Dupont J, et al. Hypothalamic and global histone H3 acetylation of spontaneous mouse mammary tumours: evidence of a beta-hydroxybutyrate paradox. *Cancer Metab.* (2017) 5:4. doi: 10.1186/s40170-017-0146-v

167. Veech RL. The therapeutic implications of ketone bodies: the effects of ketosis, ketogenic diet, redox states, lipid peroxidation and induces plasma membrane blebbing in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. *Prostaglandins Leukot Essent Fatty Acids.* (2004) 70:309–19. doi: 10.1016/j.plfa.2003.09.007

168. Veech RL, Todd King M, Pawlosky R, Kashiyama Y, Bradshaw PC, Curtis W. The great controlling nucleotide coenzymes. *IUBMB Life.* (2019) 71:565–79. doi: 10.1002/iub.1997

169. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are
associated with inhibition of apoptosis in breast epithelial cells. *Cancer Res.* (2004) 64:1757–64. doi: 10.1158/0008-5472.CAN-03-2546

193. Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. *J Neuro Oncol.* (2014) 117:125–31. doi: 10.1007/s10960-014-1362-0

194. Rieger J, Bahr O, Maurer GD, Hattingen E, Franz K, Brucker D, et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. *Int J Oncol.* (2014) 44:1843–52. doi: 10.3892/ijo.2014.2382

195. De Beer JC, Liebenberg L. Does cancer risk increase with HbA1c, independent of diabetes? *Br J Cancer.* (2014) 110:2361–8. doi: 10.1038/bjc.2014.150

196. Wu K, Yu X, Huang Z, Zhu D, Yi X, Wu YL, et al. Targeting of PP2Cdelta By a small molecule C23 inhibits high glucose-induced breast cancer progression in vivo. *Antioxid Redox Signal.* (2019) 30:1983–98. doi: 10.1089/ars.2017.7486

197. Meidenbauer JJ, Mukherjee P, Seyfried TN. The glucose ketone index calculator: a simple tool to monitor therapeutic efficacy for metabolic management of brain cancer. *Nutr Metab.* (2015) 12:12. doi: 10.1186/s12986-015-0099-2

198. Emond JA, Pierce JP, Natarajan L, Gapuz LR, Nguyen J, Parker BA, et al. Risk of breast cancer recurrence associated with carbohydrate intake and tissue expression of IGFI receptor. *Cancer Epidemiol Biomark Prev.* (2014) 23:1273–9. doi: 10.1158/1055-9965.EPI-13-1218

199. Klement RJ. Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on evidence and confirmation. *Med Oncol.* (2017) 34:132. doi: 10.1007/s12032-017-0991-5

200. Santos JG, Souza Da Cruz WM, Schonthal AH, Salazar MD, Fontes CA, Quirico-Santos T, et al. Efficacy of a ketogenic diet with concomitant intranasal perillyl alcohol as a novel strategy for the therapy of recurrent glioblastoma. *Onc Lett.* (2018) 15:1263–70. doi: 10.3892/ol.2017.7486

201. Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. *J Neuro Oncol.* (2014) 117:125–31. doi: 10.1007/s10960-014-1362-0

202. Emond JA, Pierce JP, Natarajan L, Gapuz LR, Nguyen J, Parker BA, et al. Risk of breast cancer recurrence associated with carbohydrate intake and tissue expression of IGFI receptor. *Cancer Epidemiol Biomark Prev.* (2014) 23:1273–9. doi: 10.1158/1055-9965.EPI-13-1218

203. Denny CA, Heinecke KA, Kim YP, Baek RC, Loh KS, Butters TD, et al. Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult sandhoff disease mice. *J Neurochem.* (2010) 113:1525–35. doi: 10.1111/j.1471-4159.2010.06733.x

204. Al-Bari MA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. *J Antimicrob Chemother.* (2015) 70:1608–21. doi: 10.1093/jac/dkv018

205. Ye H, Chen M, Cao F, Huang H, Zhan R, Zheng X. Chloroquine, an autophagy inhibitor, potentiates the radiosensitivity of glioma initiating cells by inhibiting autophagy and activating apoptosis. *BMC Neurol.* (2016) 16:178. doi: 10.1186/s12883-016-0700-6

206. Hrabak A, Sefrioui H, Vercruysse V, Temesi A, Bajor T, Vray B. Action of chloroquine on nitric oxide production and parasite killing by macrophages. *Eur J Pharmacol.* (1998) 354:83–90. doi: 10.1016/S0014-2999(98)00427-0

207. Yang C, Ko B, Hensley CT, Jiang L, Wasti AT, Kim J, et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. *Mol Cell.* (2014) 56:414–24. doi: 10.1016/j.molcel.2014.09.025

208. Shelton LM, Huysentruyt LC, Seyfried TN. Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model. *Inter J Cancer.* (2010) 127:2478–85. doi: 10.1002/jjc.25431

209. Lemberg KM, Voronov JJ, Rais R. We’re not DON Yet: optimal dosing and prodrug delivery of 6-Diazo-5-oxo-L-norleucine. *Mol Cancer Ther.* (2018) 17:1824–32. doi: 10.1158/1535-7163.MCT-17-1148

210. Kalamian M. KETO for CANCER: Ketogenic Metabolic Therapy as a Targeted Nutritional Strategy. White River Junction, VT: Chelsea Green (2017).

211. Mukherjee SM. Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic non-small cell lung cancer. *Int J Hyperthermia.* (2019) 36:446–55. doi: 10.1080/02656736.2019.1589584

212. Elsakka AMA, Bary MA, Abdelzaher E, Elmaggar M, Kalamian M, Mukherjee P, et al. Management of glioblastoma multiforme in a patient treated with ketogenic metabolic therapy and modified standard of care: A 24-month follow-up. *Front Nutr.* (2018) 5:20. doi: 10.3389/fnut.2018.00020

213. Arens NC, West ID. Press-pulse: a general theory of mass extinction? *Paleobiology.* (2008) 34:456–71. doi: 10.1666/07034.1

214. Mukherjee P, Abate LE, Seyfried TN. Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. *Clin Cancer Res.* (2004) 10:5622–9. doi: 10.1158/1078-0432.CCR-04-0308

215. Marsh J, Mukherjee P, Seyfried TN. Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. *Clin Cancer Res.* (2008) 14:7751–62. doi: 10.1158/1078-0432.CCR-08-0213

216. Seyfried TN, Mukherjee P. Targeting energy metabolism in brain cancer: review and hypothesis. *Nutr Metab.* (2005) 2:30. doi: 10.1186/1743-7075-2-30

Conflict of Interest: MK was employed by Dietary Therapies LLC.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Seyfried, Mukherjee, Iyikesici, Slomcz, Kalamian, Spinosa and Chinopoulos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.